Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20089 + Bevacizumab vs Chemotherapy + Bevacizumab in Platinum-sensitive Recurrent Ovarian Cancer
NCT07821606Phase 3Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Nov 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mocertatug rezetecan in ovarian cancer (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Progression-Free Survival up to 3 years. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07821606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07821606.